Eyedetec

What Eyedetec does

Eyedetec Medical, Inc. is a privately held medical device company headquartered in Danville, California, founded in 2010 and operating with 1–10 employees. The company develops the Eye Lipid Mobilizer (ELM), a wearable, facial-mask-style device for treatment of chronic dry eye disease (DED) that targets the roughly 30 million Americans affected by the condition, a market growing approximately 9% annually. The ELM combines three physical mechanisms — controlled heat application, a proprietary method called Vibration Induced Shear Thinning (VIST) that reduces the viscosity of meibomian gland oils under shear stress, and mechanical stimulation of the fifth cranial nerve to trigger a reflex that activates the lacrimal functional unit. The device is designed for in-office fitting by an eye care professional followed by patient-administered at-home use, addressing root-cause meibomian gland dysfunction rather than symptomatic relief alone.

The company's revenue model relies on hardware sales of the ELM device plus a physician-driven professional services component, where eye care professionals generate revenue via reimbursement for DED management services using ELM. The U.S. go-to-market is a direct physician partner program recruiting optometrists and ophthalmologists to become early adopters; internationally, the company holds an exclusive license, supply, and distribution agreement with Zhaoke Ophthalmology Limited covering Asian markets, signed June 2023. Pricing has not been publicly disclosed; the company positions ELM as an affordable alternative to existing DED treatments costing several hundred dollars per month.

The ELM device is pending FDA 510(k) clearance and is not commercially available for sale in the United States. Leadership includes founder and inventor Barry Linder, MD (President & CEO), a Chief Commercial Officer (John Frantzis), CTO (Peter King), VP of Sales (Cary Greene), and independent director Tom Dunlap, who joined the board in July 2024 with extensive ophthalmic industry executive experience. No institutional funding rounds or revenue figures have been disclosed; the company operates with a small team and a clear pre-commercial posture centered on regulatory clearance and physician channel buildout.

Name

Eyedetec

Legal name

Eyedetec Medical, Inc.

Website

https://eyedetec.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

Eyedetec Medical, Inc. is a private Danville, CA medical device company developing the ELM (Eye Lipid Mobilizer), a heat, vibration, and neuromodulation device for chronic dry eye disease, targeting the 30 million+ Americans with DED.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Ophthalmic Goods Manufacturing (339115)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Ophthalmic Goods (3851)

akta.pro primary industry

Dry Eye & Ocular Surface Devices (Meibography, Tear Osmolarity, IPL, Thermal Pulsation) (HLAHAJAF)

Keywords

• Ophthalmic medical devices
• Dry eye treatment
• Meibomian gland dysfunction
• Chronic dry eye therapy
• Ocular surface treatment

Headquarters

HQ city

Danville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. ELM Device Sales: The company generates revenue through the sale of the ELM (Eye Lipid Mobilizer) medical device. The product is designed for both clinical office use and home use, with initial in-office treatment customized by physicians followed by patient use at home.
2. Physician Partnership/Reimbursement: ECPs (Eye Care Professionals) can generate revenue through reimbursement for DED management services using the ELM device, providing attractive margins and significant revenue generating opportunities for physician partners.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Eyedetec Medical develops and commercializes the Eye Lipid Mobilizer® (ELM™), a proprietary medical device for treating chronic dry eye disease. The device combines therapeutic heat, Vibration Induced Shear Thinning™ (VIST), and mechanical neuromodulation to liquefy and express meibomian gland oils, addressing the root cause of evaporative dry eye. It is designed for both in-office clinician use and at-home patient use, providing continuity of care, and is currently pending FDA 510(k) clearance for U.S. commercial availability.

Product overview

Eyedetec Medical, Inc. offers a single core product—the Eye Lipid Mobilizer® (ELM™)—a medical therapy device designed for the treatment of chronic dry eye disease (DED). The ELM™ is a proprietary device that combines heat therapy, vibration-induced shear thinning, and neuromodulation to address the underlying cause of evaporative dry eye by mobilizing and expressing liquefied meibomian gland oils. The product is intended for use in both clinical (doctor's office) and home settings, with initial fitting performed by a physician. The company also mentions one commercial product for mild evaporative dry eye disease, while the ELM™ pending FDA clearance targets moderate to severe disease.

Differentiator

Problem solved

Functional benefit

Brands

• ELM (Eye Lipid Mobilizer): Medical device for treatment of chronic dry eye disease using heat, vibration, and mechanical stimulation technologies.

Products and services

• Eye Lipid Mobilizer® (ELM™) A proprietary facial-mask-form-factor medical device for the treatment of chronic dry eye disease (DED) that combines therapeutic heat, Vibration Induced Shear Thinning™ (VIST), and mechanical neuromodulation to liquefy and express meibomian gland oils and address the root cause of evaporative dry eye. Designed for both in-office clinician use and at-home patient use, with initial fitting by a physician. Targeted at optometrists, ophthalmologists, and their chronic DED patients. Pending FDA 510(k) clearance for U.S. commercial availability.

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Zhaoke Ophthalmology LimitedcoreChannel Partner/ Reseller/ Distributor · 13 June 2023Zhaoke Ophthalmology Limited, a leading ophthalmic pharmaceutical company dedicated to R&D, manufacturing and commercialization of therapies addressing unmet medical needs, entered into an exclusive license, supply and distribution agreement with Eyedetec Medical to commercialize the Eye Lipid Mobilizer for the treatment of dry eye disease. Zhaoke specializes in the Asian market, expanding ELM's geographic reach beyond the US.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Alcon: Global ophthalmic incumbent offering the iLux MGD treatment device plus the Systane dry eye portfolio; competes with Eyedetec across both the in-office device category and downstream consumer/artificial-tear adjacencies.
• Bausch + Lomb: Major ophthalmic incumbent with both pharmaceutical (Loteprednol, Miebo) and consumer (Biotrue, Soothe XP) dry eye franchises; a distribution, M&A, or strategic partner candidate that Eyedetec may encounter through Tom Dunlap's board relationships.
• Novartis (Sandoz / Xiidra): Markets Xiidra (lifitegrast), another leading prescription dry eye therapy; relevant incumbent therapy Eyedetec must displace or complement in the chronic DED management paradigm.
• AbbVie (Allergan Aesthetics / Restasis): Sells Restasis (cyclosporine ophthalmic emulsion), the leading prescription pharmaceutical for chronic dry eye; Eyedetec explicitly positions ELM against the limitations of eye drops like Restasis, which are expensive and address symptoms rather than root cause.
• Johnson & Johnson Vision (TearScience / LipiFlow): Acquired TearScience and commercializes LipiFlow, the market-leading thermal pulsation device for evaporative dry eye; sets the benchmark Eyedetec must beat on clinical evidence, reimbursement, and installed-base inertia.

Direct peers

• Lumenis (Boston Scientific): Markets the M22 IPL platform with an FDA-cleared indication for dry eye due to meibomian gland dysfunction; an established in-office device modality that Eyedetec's vibration/heat/neuromodulation approach must differentiate against on outcomes and price.
• Sight Sciences: Direct competitor developing the TearCare system for meibomian gland dysfunction and dry eye disease, targeting the same optometrist/ophthalmologist channel with an in-office thermal device; Eyedetec will compete head-to-head for the same ECP relationships.

Emerging players

• Aldeyra Therapeutics: Late-stage clinical developer of reproxalap, a novel small-molecule dry eye therapy; competes for the same patient population and represents a potential therapeutic disruption to device-based approaches like ELM.
• Mibo Medical (MiBo Thermoflo): Emerging direct competitor offering the MiBo Thermoflo thermoelectric heat therapy device for dry eye; comparable in-office-plus-home narrative to ELM and competes for the same optometry channel.
• Oyster Point Pharma (Viatris): Developed Tyrvaya (varenicline nasal spray) for dry eye disease, representing a novel non-drop delivery mechanism; an emerging prescription alternative targeting the same chronic DED patient population Eyedetec is pursuing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/eyedetec

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eyedetec